<DOC>
	<DOC>NCT00193297</DOC>
	<brief_summary>The purpose of this study is to evaluate the feasibility and toxicity of the combination of paclitaxel, carboplatin, and topotecan in patients with previously untreated, stage III or IV epithelial ovarian carcinoma or primary peritoneal carcinoma. We will also make a preliminary evaluation of the efficacy of this three drug regimen in the initial treatment of these patients.</brief_summary>
	<brief_title>Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma</brief_title>
	<detailed_description>Upon determination of eligibility, all patients will be receive: Paclitaxel + Carboplatin + Topotecan a maximum of six courses of chemotherapy will be given at 21 day intervals</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>To be included in this study, you must meet the following criteria: Epithelial ovarian carcinoma or primary peritoneal carcinoma Willing to consider secondlook surgery to evaluate response if necessary No previous treatment with chemotherapy or radiation therapy Ability to perform activities of daily living with minimal assistance Adequate bone marrow, liver and kidney function Written informed consent You cannot participate in this study if any of the following apply to you: Age &lt; 18 years Brain metastases Recent history of significant heart disease within 6 months Other significant medical conditions Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Ovary Cancer</keyword>
</DOC>